Europe medical foods for inborn errors of metabolism is projected to register a CAGR of 11.9% in the forecast period of 2020 to 2027. The new market report contains data for the historic year 2018, the base year of calculation is 2019 and the forecast period is 2020 to 2027
Market Segmentation:
Europe Medical Foods For Inborn Errors of Metabolism Market, By Product (Amino Acid, Glytactin with GMP Amino Acid-Modified Infant Formula with Iron, Low-Calcium/Vitamin D-Free Infant Formula With Iron, Low Protein Food and Others), Age Group (Infants, Weaning, Adolescent, Adults), Diseases (Phenylketonuria (PKU), Maple Syrup Urine Disease (MSUD), Homocystinuria, Methylmalonic Acidemia, Organic Acidurias, Propionic Acidemia, Isovaleric Acidemia, Disorders of Leucine Metabolism, Glutaric Acidemia Type I Renal Disease, Tyrosinemia Types I and II, Urea Cycle Disorders and Others), Forms (Powder, Liquids, gels and Others), Packaging (Can, Jar, Packets, Bottle and Others), Distribution Channel (Retail Pharmacies, Hospital Pharmacies, Drugs Stores, Online Pharmacies and Others), Country (Germany, U.K., France, Italy, Spain, Switzerland, Netherlands, Belgium, Russia, Poland, Denmark Turkey and rest of Europe) Industry Trends & Forecast to 2020

Some of the major factors contributing to the growth of the Europe medical foods for inborn errors of metabolism market are:

- Increase in the new born screening procedures
- Preference of dietary supplements over enzyme replacement therapy

Market Players:

The key market players for Europe medical foods for inborn errors of metabolism market are listed below:

- Nestle Health Science (A subsidiary of Nestle)
- Nutricia (A subsidiary of Danone)
- Abbott
- Mead Johnson & Company, LLC (A subsidiary of Reckitt Benckiser)
- BioMarin Pharmaceutical, Ajinomoto Cambrooke, Inc. (A subsidiary of Ajinomoto)
- Poa Pharma
- PKU-MDmil
- Dr.Schar AG/SPA
- Primus Pharmaceuticals, Inc
- Pristine Organics Pvt. Ltd
- APR
- Promin Metabolics